Search Results - "Stroyakovsky, Daniil L"

A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer by Socinski, Mark A, Manikhas, Georgiy M, Stroyakovsky, Daniil L, Makhson, Anatoly N, Cheporov, Sergey V, Orlov, Sergei V, Yablonsky, Petr K, Bhar, Paul, Iglesias, Jose

“…This nonrandomized study aimed to identify the optimal dose of every-3-week (q3w) and weekly nab-paclitaxel plus q3w carboplatin as first-line therapy in…”
Get more information

Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer by Schmid, Peter, Geyer Jr, Charles E., Harbeck, Nadia, Rimawi, Mothaffar, Hurvitz, Sara, Martín, Miguel, Loi, Sherene, Saji, Shigehira, Jung, Kyung Hae, Werutsky, Gustavo, Stroyakovsky, Daniil L., López-Valverde, Vanesa, Davis, Michael, Crnjevic, Tanja Badovinac, Perez-Moreno, Pablo D., Bardia, Aditya

“…BACKGROUND Endocrine therapies (ETs) that target estrogen receptor (ER) activity and/or estrogen synthesis are the mainstay of ER+ breast cancer (BC)…”
Get full text

Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07) by Hamilton, Erika, Jhaveri, Komal, Loi, Sherene, Anders, Carey, Schmid, Peter, Penkov, Konstantin, Artamonova, Elena, Zhukova, Lyudmila, Stroyakovsky, Daniil L., Doval, Dinesh Chandra, Villanueva, Rafael, Michelini, Flavia, Chandarlapaty, Sarat, Wilson, Matt, Boston, Sarice R., Konpa, Adam, Mondal, Shoubhik, Andre, Fabrice

“…Background: In trials of HER2+ metastatic breast cancer (mBC), trastuzumab deruxtecan (T-DXd) monotherapy showed durable efficacy (DESTINY-Breast01) and…”
Get full text

Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients by Stenina, Marina B., Ignatova, Ekaterina, Frolova, Mona A., Burdaeva, Olga N., Nechaeva, Marina P., Kopp, Mikhail V., Udovitsa, Dmitry P., Kotiv, Bogdan N., Alekseev, Sergiy M., Stroyakovsky, Daniil L., Sheveleva, Ludmila P., Khorinko, Andrey V., Prokopenko, Tatiana I., Shapovalova, Julia S., Jelvakova, Irina A., Ivanov, R., Filon, Olga V., Tjulandin, Sergei

“…Abstract only…”
Get full text

Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients by Orlov, Sergey V., Burdaeva, Olga N., Nechaeva, Marina P., Kopp, Mikhail V., Kotiv, Bogdan N., Sheveleva, Ludmila P., Gladkov, Oleg A., Khorinko, Andrey V., Prokopenko, Tatiana I., Shapovalova, Julia S., Jelvakova, Irina A., Kovalenko, Nadezhda V., Stroyakovsky, Daniil L., Pecheniy, Aleksandr P., Ivanov, R., Filon, Olga V., Tjulandin, Sergei

“…Abstract only…”
Get full text

COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma by Long, Georgina V., Stroyakovsky, Daniil L., Gogas, Helen, Levchenko, Eugeny, de Braud, Filippo, Larkin, James M. G., Garbe, Claus, Jouary, Thomas, Hauschild, Axel, Grob, Jean Jacques, Chiarion-Sileni, Vanna, Lebbe, Celeste, Mandalà, Mario, Millward, Michael, DeMarini, Douglas James, Irani, Jhangir G, Le, Ngocdiep, Casey, Michelle, Patel, Kiran, Flaherty, Keith

“…Abstract only…”
Get full text